AI Terminal
BIOPHARMA CREDIT PLC
Report Publication Announcement • Feb 27, 2024
4973_rns_2024-02-27_2fa9b424-bdf7-482f-a486-a3377605e3a2.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5273E
BioPharma Credit PLC
27 February 2024
27 February 2024
BIOPHARMA CREDIT PLC
(the "Company")
NOTICE OF FULL YEAR RESULTS
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the year ended 31 December 2023 on Wednesday 27 March 2024.
A management presentation for research analysts will be delivered at 2:00pm GMT through a webcast facility. To register to attend or request details, RSVP to [email protected].
-Ends-
Enquiries
BioPharma Credit PLC
via Link Company Matters Limited
Company Secretary
+44 (0) 333 300 1950
Buchanan
+44 (0)20 7466 5000
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORGZGZZGNVGDZG